Medmira Inc (MMIRF) 0.0219 $MMIRF
MedMira Reports Second Quarter Results for FY2016
Marketwired - Thu Mar 24, 4:30PM CDT
MedMira Inc. (MedMira) (TSX VENTURE: MIR) reported today on its financial results for the three and six month periods ended January 31, 2016.
MIR.VN: 0.035 (-0.005)
MedMira Announces Annual Shareholders Meeting Results
Marketwired - Mon Feb 01, 4:30PM CST
MedMira Inc. (MedMira) (TSX VENTURE: MIR) held its 2016 Annual General and Special Meeting of Shareholders on January 29, 2016. Incumbent Directors Mr. Hermes Chan, Mr. Marvyn Robar, and Mr. Romano Robusto were re-elected. Dr. Philippe Dro, the OnSite Lab Holdings AG representative, and Dr. Martial Lacroix were newly elected to the MedMira Board of Directors.
MIR.VN: 0.035 (-0.005)
MedMira Directors Granted Stock Options
Marketwired - Fri Jan 08, 4:01PM CST
MedMira Inc. (MedMira) (TSX VENTURE: MIR) has granted the Company's Board of Directors options to purchase common shares under its Stock Option Plan which was approved by shareholders at the Company's Annual General and Special Meeting on January 25, 2013. Mr. Marvyn Robar, Mr. Hermes Chan, Dr. Philippe Dro, and Mr. Romano Robusto were granted a total of 779,167 options at an exercise price of $0.10 per share and exercisable for a period of three years ending January 7, 2019.
MIR.VN: 0.035 (-0.005)
MedMira Reports Fiscal First Quarter 2016 Financial Results
Marketwired - Mon Dec 14, 4:32PM CST
MedMira Inc. (MedMira) (TSX VENTURE: MIR), reported today on its financial results for the three month period ending October 31, 2015. The Company recorded a 210% increase in revenue and a 202% increase in gross profit during the first quarter, compared to the same period last year.
MIR.VN: 0.035 (-0.005)
HIV/AIDS Testing - Global Strategic Business Report 2015-2020 - Screening Tests, Confirmatory Tests and Monitoring Tests
M2 - Wed Dec 09, 3:27AM CST
Research and Markets (http://www.researchandmarkets.com/research/582pp5/hivaids_testing) has announced the addition of the "HIV/AIDS Testing - Global Strategic Business Report" report to their offering. This report analyzes the worldwide markets for HIV/AIDS Testing in Thousands (volume) and US$ Thousand (value) by the following Product Segments: HIV/AIDS Screening Tests, HIV/AIDS Confirmatory Tests, and HIV/AIDS Monitoring Tests. The report provides separate comprehensive analytics for the US, Canada, Japan, Europe, Asia-Pacific, Latin America, and Rest of World. Annual estimates and forecasts are provided for the period 2014 through 2020. Also, a seven-year historic analysis is provided for these markets. Market data and analytics are derived from primary and secondary research. Company profiles are primarily based on public domain information including company URLs. The report profiles 42 companies including many key and niche players such as - Abbott Laboratories, Inc. (US) - Abbott Molecular, Inc. (US) - Adaltis S.r.l. (Italy) - Alere (US) - Beckman Coulter, Inc. (US) - bioM?rieux SA (France) - Bio-Rad Laboratories, Inc. (US) - Calypte Biomedical Corporation (US) - Chembio Diagnostic Systems, Inc. (US) - Hologic, Inc. (US) - Fujirebio Europe N.V. (Belgium) - MedMira Inc. (Canada) - OraSure Technologies, Inc. (US) - Ortho-Clinical Diagnostics, Inc. (US) - Quest Diagnostics, Inc. (US) - Roche Diagnostics (Switzerland) - Siemens Healthcare Diagnostics, Inc. (US) - Trinity Biotech Plc. (Ireland) Key Topics Covered: 1. INDUSTRY OVERVIEW 2. GROWTH DRIVERS AND MARKET TRENDS 3. HIV/AIDS STATISTICS 4. HIV/AIDS: UNDERSTANDING THE DISEASE 5. DIAGNOSIS OF HIV/AIDS 6. PRODUCT APPROVALS & LAUNCHES 7. RECENT INDUSTRY ACTIVITY 8. FOCUS ON SELECT GLOBAL PLAYERS 9. GLOBAL MARKET PERSPECTIVE Total Companies Profiled: 42 (including Divisions/Subsidiaries - 47) - The United States (33) - Canada (2) - Europe (
- - France (2) - - Italy (2) - - Rest of Europe (4) - Asia-Pacific (Excluding Japan) (4) For more information visit http://www.researchandmarkets.com/research/58...ds_testing
ABT: 44.72 (-0.20), DGX: 84.70 (-0.55), TRIB: 12.10 (-0.41), HOLX: 38.10 (-0.41), OSUR: 7.00 (-0.03)
MedMira Debuts Reveal(R) G4 Rapid HIV Test at National HIV Prevention Conference
Marketwired - Mon Dec 07, 8:22AM CST
Editors Note: There is an image associated with this press release.
MIR.VN: 0.035 (-0.005)
MedMira Reports 2015 Fourth Quarter and Year End Financial Results
Marketwired - Tue Nov 24, 4:31PM CST
MedMira Inc. (MedMira) (TSX VENTURE: MIR) reported today on its financial results for the quarter and year ended July 31, 2015. The Company recorded a 60% increase in revenue and a 52% increase in gross profit at the fiscal year end compared to the prior year.
MIR.VN: 0.035 (-0.005)
MedMira Receives FDA Approval for the Reveal(R) G4 Rapid HIV-1 Antibody Test
Marketwired - Mon Oct 19, 9:01AM CDT
Editors Note: There is a photo associated with this press release.
MIR.VN: 0.035 (-0.005)
IIROC Trade Halt - Medmira Inc.
Newsfile Corp - Mon Oct 19, 7:20AM CDT
The following issues have been halted by IIROC:
MedMira Closes Investment from OnSite Lab
Marketwired - Tue Sep 08, 8:28AM CDT
MedMira Inc. (MedMira) (TSX VENTURE: MIR) has closed the CAD $5 million equity investment with OnSite Lab Holding AG (OnSite Lab) announced September 2, 2015. OnSite Lab is the Company's controlling shareholder and has previously made investments in MedMira totalling CAD $18.7 million.
MIR.VN: 0.035 (-0.005)
MedMira Targets Technology Promotion with Latest Investment from OnSite Lab
Marketwired - Wed Sep 02, 7:30PM CDT
MedMira Inc. (MedMira) (TSX VENTURE: MIR) is entering into a CAD $5 million investment with OnSite Lab Holding AG (OnSite Lab) to increase promotion and brand building to position the Company's proprietary Rapid Vertical Flow (RVF) Technology(TM) as a dominant platform in the rapid diagnostics industry.
MIR.VN: 0.035 (-0.005)
MedMira Board Reinforces Biotech Bench Strength with New Appointment
Marketwired - Mon Aug 17, 3:30PM CDT
MedMira Inc. (MedMira) (TSX VENTURE: MIR) announced today that controlling shareholder, OnSite Lab Holdings AG (OnSite Lab) has appointed Dr. Philippe Dro as its representative on the Company's Board of Directors, effective as of August 7, 2015. Dr. Dro replaces Dr. Michael Sidler who has served on MedMira's Board since 2012.
AGN: 253.01 (-0.18), MIR.VN: 0.035 (-0.005)
MedMira Reports Second Quarter Results for FY2016
Marketwired - Thu Mar 24, 4:30PM CDT
MedMira Inc. (MedMira) (TSX VENTURE: MIR) reported today on its financial results for the three and six month periods ended January 31, 2016.
MIR.VN: 0.035 (-0.005)
MedMira Announces Annual Shareholders Meeting Results
Marketwired - Mon Feb 01, 4:30PM CST
MedMira Inc. (MedMira) (TSX VENTURE: MIR) held its 2016 Annual General and Special Meeting of Shareholders on January 29, 2016. Incumbent Directors Mr. Hermes Chan, Mr. Marvyn Robar, and Mr. Romano Robusto were re-elected. Dr. Philippe Dro, the OnSite Lab Holdings AG representative, and Dr. Martial Lacroix were newly elected to the MedMira Board of Directors.
MIR.VN: 0.035 (-0.005)
MedMira Directors Granted Stock Options
Marketwired - Fri Jan 08, 4:01PM CST
MedMira Inc. (MedMira) (TSX VENTURE: MIR) has granted the Company's Board of Directors options to purchase common shares under its Stock Option Plan which was approved by shareholders at the Company's Annual General and Special Meeting on January 25, 2013. Mr. Marvyn Robar, Mr. Hermes Chan, Dr. Philippe Dro, and Mr. Romano Robusto were granted a total of 779,167 options at an exercise price of $0.10 per share and exercisable for a period of three years ending January 7, 2019.
MIR.VN: 0.035 (-0.005)
MedMira Reports Fiscal First Quarter 2016 Financial Results
Marketwired - Mon Dec 14, 4:32PM CST
MedMira Inc. (MedMira) (TSX VENTURE: MIR), reported today on its financial results for the three month period ending October 31, 2015. The Company recorded a 210% increase in revenue and a 202% increase in gross profit during the first quarter, compared to the same period last year.
MIR.VN: 0.035 (-0.005)
HIV/AIDS Testing - Global Strategic Business Report 2015-2020 - Screening Tests, Confirmatory Tests and Monitoring Tests
M2 - Wed Dec 09, 3:27AM CST
Research and Markets (http://www.researchandmarkets.com/research/582pp5/hivaids_testing) has announced the addition of the "HIV/AIDS Testing - Global Strategic Business Report" report to their offering. This report analyzes the worldwide markets for HIV/AIDS Testing in Thousands (volume) and US$ Thousand (value) by the following Product Segments: HIV/AIDS Screening Tests, HIV/AIDS Confirmatory Tests, and HIV/AIDS Monitoring Tests. The report provides separate comprehensive analytics for the US, Canada, Japan, Europe, Asia-Pacific, Latin America, and Rest of World. Annual estimates and forecasts are provided for the period 2014 through 2020. Also, a seven-year historic analysis is provided for these markets. Market data and analytics are derived from primary and secondary research. Company profiles are primarily based on public domain information including company URLs. The report profiles 42 companies including many key and niche players such as - Abbott Laboratories, Inc. (US) - Abbott Molecular, Inc. (US) - Adaltis S.r.l. (Italy) - Alere (US) - Beckman Coulter, Inc. (US) - bioM?rieux SA (France) - Bio-Rad Laboratories, Inc. (US) - Calypte Biomedical Corporation (US) - Chembio Diagnostic Systems, Inc. (US) - Hologic, Inc. (US) - Fujirebio Europe N.V. (Belgium) - MedMira Inc. (Canada) - OraSure Technologies, Inc. (US) - Ortho-Clinical Diagnostics, Inc. (US) - Quest Diagnostics, Inc. (US) - Roche Diagnostics (Switzerland) - Siemens Healthcare Diagnostics, Inc. (US) - Trinity Biotech Plc. (Ireland) Key Topics Covered: 1. INDUSTRY OVERVIEW 2. GROWTH DRIVERS AND MARKET TRENDS 3. HIV/AIDS STATISTICS 4. HIV/AIDS: UNDERSTANDING THE DISEASE 5. DIAGNOSIS OF HIV/AIDS 6. PRODUCT APPROVALS & LAUNCHES 7. RECENT INDUSTRY ACTIVITY 8. FOCUS ON SELECT GLOBAL PLAYERS 9. GLOBAL MARKET PERSPECTIVE Total Companies Profiled: 42 (including Divisions/Subsidiaries - 47) - The United States (33) - Canada (2) - Europe (
- - France (2) - - Italy (2) - - Rest of Europe (4) - Asia-Pacific (Excluding Japan) (4) For more information visit http://www.researchandmarkets.com/research/58...ds_testing ABT: 44.72 (-0.20), DGX: 84.70 (-0.55), TRIB: 12.10 (-0.41), HOLX: 38.10 (-0.41), OSUR: 7.00 (-0.03)
MedMira Debuts Reveal(R) G4 Rapid HIV Test at National HIV Prevention Conference
Marketwired - Mon Dec 07, 8:22AM CST
Editors Note: There is an image associated with this press release.
MIR.VN: 0.035 (-0.005)
MedMira Reports 2015 Fourth Quarter and Year End Financial Results
Marketwired - Tue Nov 24, 4:31PM CST
MedMira Inc. (MedMira) (TSX VENTURE: MIR) reported today on its financial results for the quarter and year ended July 31, 2015. The Company recorded a 60% increase in revenue and a 52% increase in gross profit at the fiscal year end compared to the prior year.
MIR.VN: 0.035 (-0.005)
MedMira Receives FDA Approval for the Reveal(R) G4 Rapid HIV-1 Antibody Test
Marketwired - Mon Oct 19, 9:01AM CDT
Editors Note: There is a photo associated with this press release.
MIR.VN: 0.035 (-0.005)
IIROC Trade Halt - Medmira Inc.
Newsfile Corp - Mon Oct 19, 7:20AM CDT
The following issues have been halted by IIROC:
MedMira Closes Investment from OnSite Lab
Marketwired - Tue Sep 08, 8:28AM CDT
MedMira Inc. (MedMira) (TSX VENTURE: MIR) has closed the CAD $5 million equity investment with OnSite Lab Holding AG (OnSite Lab) announced September 2, 2015. OnSite Lab is the Company's controlling shareholder and has previously made investments in MedMira totalling CAD $18.7 million.
MIR.VN: 0.035 (-0.005)
MedMira Targets Technology Promotion with Latest Investment from OnSite Lab
Marketwired - Wed Sep 02, 7:30PM CDT
MedMira Inc. (MedMira) (TSX VENTURE: MIR) is entering into a CAD $5 million investment with OnSite Lab Holding AG (OnSite Lab) to increase promotion and brand building to position the Company's proprietary Rapid Vertical Flow (RVF) Technology(TM) as a dominant platform in the rapid diagnostics industry.
MIR.VN: 0.035 (-0.005)
MedMira Board Reinforces Biotech Bench Strength with New Appointment
Marketwired - Mon Aug 17, 3:30PM CDT
MedMira Inc. (MedMira) (TSX VENTURE: MIR) announced today that controlling shareholder, OnSite Lab Holdings AG (OnSite Lab) has appointed Dr. Philippe Dro as its representative on the Company's Board of Directors, effective as of August 7, 2015. Dr. Dro replaces Dr. Michael Sidler who has served on MedMira's Board since 2012.
AGN: 253.01 (-0.18), MIR.VN: 0.035 (-0.005)
